Gynecologic Cancer News

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

Black women undergoing treatment for gynecologic cancer reported significantly higher levels of race-associated stress compared with white women, according to study results.

Women diagnosed with breast or gynecologic cancers underutilized both assisted reproductive technology and fertility-sparing oncology care, according to study results.

Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers, according to a results of the phase 3 SORAYA study.

Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors in 75% of patients with recurrent or persistent estrogen receptor-positive, or ER-positive, endometrial cancer.

Women with gynecologic cancer and COVID-19 demonstrated a high risk for hospitalization, cancer treatment delays and death, according to a study presented at Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.

The FDA approved pembrolizumab for certain women with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.

A trained artificial intelligence model predicted treatment outcomes before surgery of women with high-grade serous ovarian cancer, according to study results.

Data published in Cell Reports Medicine showed that endometriosis was genetically linked to ovarian cancer.

Cancer screening remains in need of urgent attention, and online resources may help facilities close gaps and address screenings missed in 2020, according to a prospective quality improvement study published in Cancer.